PMID- 36091128 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220913 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 12 DP - 2022 TI - Microwave ablation plus camrelizumab monotherapy or combination therapy in non-small cell lung cancer. PG - 938827 LID - 10.3389/fonc.2022.938827 [doi] LID - 938827 AB - PURPOSE: Immunotherapy has become widely applied in non-small cell lung cancer (NSCLC) patients. However, the relatively low response rate of immunotherapy monotherapy restricts its application. Combination therapy improves the response rate and prolongs patient survival; however, adverse events (AEs) associated with immunotherapies increase with combination therapy. Therefore, exploring combination regimens with equal efficacy and fewer AEs is urgently required. The aim of this study was to evaluate the efficacy and safety of microwave ablation (MWA) plus camrelizumab monotherapy or combination therapy in NSCLC. MATERIALS AND METHODS: Patients with pathologically confirmed, epidermal growth factor receptor/anaplastic lymphoma kinase-wild-type NSCLC were retrospectively enrolled in this study. Patients underwent MWA to the pulmonary lesions first, followed by camrelizumab monotherapy or combination therapy 5-7 days later. Camrelizumab was administered with the dose of 200 mg every 2 to 3 weeks. Treatment was continued until disease progression or intolerable toxicities. The technical success and technique efficacy of ablation, objective response rate (ORR), progression-free survival (PFS), overall survival (OS), complications of ablation, and AEs were recorded. RESULTS: From January 1, 2019 to December 31, 2021, a total of 77 patients underwent MWA and camrelizumab monotherapy or combination therapy. Technical success was achieved in all patients (100%), and the technique efficacy was 97.4%. The ORR was 29.9%. The PFS and OS were 11.8 months (95% confidence interval, 9.5-14.1) and not reached, respectively. Smoking history and response to camrelizumab were correlated with PFS, and response to camrelizumab was correlated with OS in both the univariate and multivariate analyses. No periprocedural deaths due to ablation were observed. Complications were observed in 33 patients (42.9%). Major complications included pneumothorax (18.2%), pleural effusion (11.7%), pneumonia (5.2%), bronchopleural fistula (2.6%), and hemoptysis (1.3%). Grade 3 or higher AEs of camrelizumab, including reactive capillary endothelial proliferation, fatigue, pneumonia, edema, and fever, were observed in 10.4%, 6.5%, 5.2%, 2.6%, and 2.6% of patients, respectively. CONCLUSION: MWA combined with camrelizumab monotherapy or combination therapy is effective and safe for the treatment of NSCLC. CI - Copyright (c) 2022 Huang, Wang, Hu, Cao, Wang, Cai, Wang, Yang, Wei and Ye. FAU - Huang, Yahan AU - Huang Y AD - Department of Oncology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Lung Cancer Institute, Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Jinan, China. AD - Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, China. FAU - Wang, Jiao AU - Wang J AD - Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China. FAU - Hu, Yanting AU - Hu Y AD - Department of Oncology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Lung Cancer Institute, Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Jinan, China. FAU - Cao, Pikun AU - Cao P AD - Department of Oncology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Lung Cancer Institute, Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Jinan, China. FAU - Wang, Gang AU - Wang G AD - Department of Oncology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Lung Cancer Institute, Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Jinan, China. FAU - Cai, Hongchao AU - Cai H AD - Department of Oncology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Lung Cancer Institute, Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Jinan, China. FAU - Wang, Meixiang AU - Wang M AD - Department of Oncology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Lung Cancer Institute, Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Jinan, China. FAU - Yang, Xia AU - Yang X AD - Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China. FAU - Wei, Zhigang AU - Wei Z AD - Department of Oncology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Lung Cancer Institute, Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Jinan, China. AD - Cheeloo College of Medicine, Shandong University, Jinan, China. FAU - Ye, Xin AU - Ye X AD - Department of Oncology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Lung Cancer Institute, Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Jinan, China. LA - eng PT - Journal Article DEP - 20220826 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC9459232 OTO - NOTNLM OT - camrelizumab OT - lung cancer OT - microwave ablation OT - objective response rate OT - overall survival OT - progression-free survival COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/09/13 06:00 MHDA- 2022/09/13 06:01 PMCR- 2022/01/01 CRDT- 2022/09/12 03:56 PHST- 2022/05/08 00:00 [received] PHST- 2022/08/02 00:00 [accepted] PHST- 2022/09/12 03:56 [entrez] PHST- 2022/09/13 06:00 [pubmed] PHST- 2022/09/13 06:01 [medline] PHST- 2022/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2022.938827 [doi] PST - epublish SO - Front Oncol. 2022 Aug 26;12:938827. doi: 10.3389/fonc.2022.938827. eCollection 2022.